These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 17486065

  • 1. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O.
    Oncogene; 2007 Oct 25; 26(49):6997-7005. PubMed ID: 17486065
    [Abstract] [Full Text] [Related]

  • 2. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
    Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O.
    Clin Cancer Res; 2010 Mar 01; 16(5):1624-33. PubMed ID: 20179234
    [Abstract] [Full Text] [Related]

  • 3. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
    Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stål O, Landberg G.
    Cancer Res; 2005 Sep 01; 65(17):8009-16. PubMed ID: 16140974
    [Abstract] [Full Text] [Related]

  • 4. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.
    J Natl Cancer Inst; 2006 May 17; 98(10):671-80. PubMed ID: 16705121
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.
    Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stål O, Linn SC, Landberg G, Michalides R.
    Breast Cancer Res Treat; 2011 Jan 17; 125(1):1-12. PubMed ID: 20213082
    [Abstract] [Full Text] [Related]

  • 7. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM.
    Breast Cancer Res Treat; 2009 Jan 17; 113(2):253-60. PubMed ID: 18299979
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 17; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
    Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.
    Breast Cancer Res; 2008 Apr 15; 10(5):R81. PubMed ID: 18823530
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2008 Mar 15; 14(6):1767-74. PubMed ID: 18347178
    [Abstract] [Full Text] [Related]

  • 20. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
    Rayala SK, Kumar R.
    Biomed Pharmacother; 2007 Aug 15; 61(7):408-11. PubMed ID: 17604944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.